Real‐world outcomes upon second‐line treatment in patients with chronic lymphocytic leukaemia

Summary For chronic lymphocytic leukaemia (CLL), targeted drugs have become the standard of care, in particular for second‐line treatment. In this study, overall survival (OS), treatment‐free survival (TFS) and adverse events (AE) were registered retrospectively in a Danish population‐based cohort u...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2023-06, Vol.201 (5), p.874-886
Main Authors: Vainer, Noomi, Aarup, Kathrine, Andersen, Michael Asger, Wind‐Hansen, Lise, Nielsen, Tine, Frederiksen, Henrik, Enggaard, Lisbeth, Poulsen, Christian Bjørn, Niemann, Carsten U., Rotbain, Emelie C.
Format: Article
Language:English
Subjects:
adverse events
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bendamustine Hydrochloride - therapeutic use
CD20 antigen
Chlorambucil
Chlorambucil - adverse effects
chronic lymphocytic leukaemia
Chronic lymphocytic leukemia
Cyclophosphamide
Fludarabine
Hematology
Humans
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Medical records
Patients
Retrospective Studies
Rituximab
Survival
targeted treatment
treatment effect
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary For chronic lymphocytic leukaemia (CLL), targeted drugs have become the standard of care, in particular for second‐line treatment. In this study, overall survival (OS), treatment‐free survival (TFS) and adverse events (AE) were registered retrospectively in a Danish population‐based cohort upon second‐line treatment for CLL. Data were collected from medical records and the Danish National CLL register. For 286 patients receiving second‐line treatment, three‐year TFS was higher upon targeted treatment (ibrutinib/venetoclax/idelalisib) [63%, 95% confidence interval (CI) 50%–76%] compared with fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab (FCR/BR) (37%, CI: 26%–48%) and chlorambucil+/−CD20‐antibody (CD20Clb/Clb) (22%, CI: 10%–33%). Upon targeted treatment, three‐year OS estimates were higher for targeted treatment (79%, CI: 68%–91%) compared with FCR/BR (70%, CI: 60%–81%) or CD20Clb/Clb (60%, CI: 47%–74%). The most common AEs were infections and haematological AEs; 92% of patients treated with targeted drugs had AEs, 53% of which were severe. Upon FCR/BR and CD20Clb/Clb, AEs were present for 75% and 53% respectively, of which 63% and 31% were severe. These real‐world data demonstrate higher TFS and a tendency towards higher OS following targeted second‐line treatment for CLL compared to chemoimmunotherapy, also for patients who may be frailer and more comorbid.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18715